This spring

The FDA just locked the July PCAC roster — and the most prescribed GH peptide is absent

This month, with the FDA's July 23–24 Pharmacy Compounding Advisory Committee meeting now under eight weeks out, the formal peptide review roster is locked. Seven substances made the agenda: BPC-157, TB-500, MOTS-c, and KPV on Day 1; Emideltide (DSIP), Semax, and Epitalon on Day 2. A second PCAC meeting — before February 2027 — was also announced, covering GHK-Cu, Melanotan II, cathelicidin LL-37, and dihexa. CJC-1295, the GHRH analog prescribed by more American wellness clinics than any other growth hormone peptide, is not on either list. Neither is ipamorelin, its near-universal stack partner. Both were removed from the FDA's Category 2 restricted list this spring — the designation that since 2023 had labeled them bulk drug substances posing significant safety risks for compounding. That removal came after Evexias Medical Group and Farmakeio Outsourcing sued the FDA for lack of transparency in how the Category 2 placements were made; the nominations were subsequently withdrawn. What the removal did not produce: a formal PCAC evaluation date, a Category 1 placement, or a compounding authorization. The [Federal Register notice from April 16, 2026](https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request) published the July agenda. CJC-1295 is not in it.

The actual biology

A GHRH analog engineered to stay in circulation long after native GHRH has cleared

Growth hormone releasing hormone is what the hypothalamus sends to the pituitary to trigger a GH pulse. The native molecule has a half-life measured in minutes — it signals, clears, and the pituitary waits for the next cue. CJC-1295 was designed to extend that signal dramatically. It is a 30-amino-acid synthetic analog of GHRH modified with a Drug Affinity Complex technology that enables it to bind to serum albumin after injection, dramatically extending circulatory residence from minutes to days. The downstream target is IGF-1: liver production of insulin-like growth factor 1, the effector molecule that GH pulses are ultimately trying to activate. That IGF-1 signal is the mechanistic basis for the body-composition, recovery, and skin-related claims attached to the GH-axis category — because IGF-1 interacts with muscle protein synthesis, fat oxidation, collagen synthesis, and tissue repair pathways. The CJC-1295 argument is that more sustained GH stimulus means more IGF-1 production, which means more opportunity for those downstream effects to accumulate. [PubMed literature on CJC-1295](https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295) tracks where this pharmacological work was established and where it remains under investigation. The logic of the mechanism is coherent. The clinical evidence for the downstream outcomes is a different document.

What the internet says

The most requested protocol in American peptide clinics — always combined with ipamorelin

CJC-1295 has been the dominant GHRH analog in American wellness clinic menus since sermorelin — its older, shorter-acting predecessor with an actual FDA drug approval history — was largely displaced in favor of the DAC-modified version. The argument for switching was practical: CJC-1295's extended half-life means less frequent dosing, and some practitioners argue it produces a steadier GH signal than sermorelin's faster clearance allows. In clinic contexts, CJC-1295 almost always appears paired with ipamorelin, a ghrelin receptor agonist that stimulates GH secretion through a second, complementary receptor pathway. The pitch for the combination is amplification: one molecule pushing the GHRH receptor, one activating the ghrelin receptor, producing a larger GH pulse than either achieves alone. The claims attached to that protocol span body composition improvement, sleep depth enhancement, faster post-training recovery, skin and hair effects, and anti-aging framing. Optimization podcasts and clinic intake materials lean heavily on the natural framing: your body's own GH, just more of it. That framing is mechanistically accurate as far as it goes. Whether more GH means better measurable clinical outcomes in healthy adults is the gap the evidence record has not closed.

What the data actually shows

A 2006 Phase 1/2 human study is still the primary evidence — and outcome trials have not followed

The human pharmacology data for CJC-1295 largely originates from a single Phase 1/2 dose-escalation study published in the Journal of Clinical Endocrinology and Metabolism, which enrolled 42 participants across five cohorts — 21 healthy adults and 21 adults with GH deficiency — and documented statistically significant, dose-dependent increases in serum GH and IGF-1, with effects persisting for up to 14 days at higher doses. That data is real. The study demonstrated that CJC-1295 does what the mechanism predicts: it pushes the GH/IGF-1 axis upward and sustains the effect over a clinically relevant window. What the study did not test: body composition as a primary endpoint, recovery outcomes, sleep architecture, skin parameters, or any of the specific health claims that now anchor clinic marketing. [ClinicalTrials.gov for CJC-1295](https://clinicaltrials.gov/search?term=CJC-1295) shows the registered study history. The quality record adds a separate note: in May 2025, the FDA classified a Class II recall for compounded CJC-1295 injectable pre-filled syringes from a Colorado compounder due to lack of assurance of sterility — the kind of manufacturing quality concern the Category 2 process was partly designed to identify. The GH/IGF-1 signal from 2006 remains the primary human evidence. A controlled trial with clinical outcomes endpoints has not followed it.

Early human — PeptideFactCheck stance

A real hormone signal in a regulatory gap — and the July calendar has no slot for it

CJC-1295 holds the Early human evidence tier on PeptideFactCheck because the clinical record contains genuine peer-reviewed pharmacology data showing GH/IGF-1 axis effects in human subjects. That distinguishes it from purely preclinical peptides. It also means the broad optimization claims attached to this compound — body composition, recovery, anti-aging — rest on endocrine markers from a Phase 1/2 study, not on controlled trials measuring the outcomes people are actually paying for. Early human: interesting enough to watch, too early for broad certainty. The regulatory picture as of May 2026 adds a specific kind of ambiguity. The Category 2 removal is real — CJC-1295 no longer carries the FDA's formal significant safety risks designation. But that removal does not place it on the [FDA's bulk drug substances compounding framework](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) Category 1 list, which is the designation that would authorize licensed 503A compounding pharmacies to prepare it for patients. The July PCAC meeting will not change that for CJC-1295. Neither will the February 2027 PCAC batch. The most prescribed GH-axis peptide in American wellness clinics is sitting in a gap — no longer formally restricted, not yet formally authorized, and not scheduled for the federal review that would move it in either direction. The endocrine signal from 2006 is still the most current clinical data available. That is a lot of weight for one study to carry.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.